Most early-stage cardiac monitoring companies don't have a technology problem — they have a go-to-market problem. The device is ready. The path to the cardiologist isn't.
// Device to doctor. That's the whole job.
Clearance gets you a product. It doesn't get you into an EP lab. Here's where clinically proven devices stall before a single patient is monitored.
Relationships are the currency that move a new monitor through a health system — and a startup doesn't have them yet at the IDNs that matter.
Economic buyer, clinical champion, or blocker? In a hospital cardiology program the roles aren't labeled. Guess wrong and the deal quietly dies.
MCT, extended Holter, and ILR coding each flow differently through hospital billing. One wrong conversation with the wrong stakeholder kills the deal.
Electrophysiology is a relationship-driven subspecialty. You get introduced, or you don't get in. A rep without that access burns months going nowhere.
Getting cardiac devices ordered. Not shipped, not cleared — ordered, by the physicians who decide whether patients wear them. That's the whole job, in three words.
We don't do that work for you — we hand your team the method to do it themselves. Built from 16 years and $50M+ in revenue inside exactly these accounts: the EP labs, the cardiology programs, the value-analysis committees, and the reimbursement conversations that decide whether your device gets used.
A fractional sales rep opens doors that close again the day they leave — you'd be renting relationships you never own. Device-to-Doctor is done with you, not for you. We coach your marketing and sales people on how a cardiac device actually moves through a U.S. health system, so the capability lives inside your company for good.
Relationships are the last mile. The repeatable method for navigating committees, champions, blockers, and reimbursement is the system. We install the system.
Your reps run the plays. We make them effective before they ever walk in the door, so every conversation lands with someone who already speaks the language.
Every account your team lands makes the next one easier. You're building institutional sales muscle — not buying a temporary lift that walks out the door.
Four stages, sequenced. Each one gets your device closer to the doctor's hands — and each one your team learns to run without us.
Map the buyers, blockers, champions, and the reimbursement path inside each target system. Know who the real decision-maker is in every account before anyone walks in.
Get into the account with a low-risk, 10–15 patient evaluation that lets the device prove itself in real clinical use — the lowest-friction way past a skeptical first conversation.
Turn early use into validation: a respected EP who advocates, clean clinical data inside a real U.S. health system, and reimbursement positioning that holds up to scrutiny.
Hand your team a replicable playbook — account profiles, objection handling, reimbursement talking points — that they can staff a sales force against and run on their own.
We coach your team to raise their odds of a yes long before they ever sit across from a buyer.
Make the device resonate before a rep ever walks in.
Get into accounts — and stay top of mind until the competitor slips.
A full-time VP of Sales runs $200K–$400K before they've opened a single door — and the relationships leave when they do. Device-to-Doctor builds the same capability across your whole team, on a monthly retainer, for a fraction of one executive hire. It's a cohort model, it's location-agnostic, and your market is wherever your device needs to go.
A thirty-minute call. No pitch. We'll talk through where your commercial build is stuck — and I'll be honest about whether this is the right fix for where you are.
Steve DeFelice · Founder